Discovering next-generation combination therapies and immunotherapies for lung cancer patients

Bidragets beskrivning

Lung cancer is the biggest cancer killer in men and the second biggest in women in Finland (Syöpärekisteri, 2018). 10-15% of the adenocarcinomas in non-smoker patients harbor mutations in epidermal growth factor (EGFR) gene. EGFR inhibitors have improved the life expectancy of these patients, but typically drug resistance forms within 9-14 months. Every cell in the tumor is different (=tumor heterogeneity), and only some cells have the capacity to form resistance. Dr. Haikala's research performed in the University of Helsinki is studying how tumor heterogeneity contributes to formation of drug-resistant miroenvironment and therapy resistance. The study aims to find better targeted and immunotherapy combinations for lung cancer patients to achieve long lasting treatment effects. The research utilizes cutting edge research models including microfluidic and organoid 3D cultures from fresh tumor tissue collected from consented patients in collaboration with the University Hospital.
Visa mer

Startår

2021

Slutår

2024

Beviljade finansiering

Heidi Haikala Orcid -palvelun logo
297 975 €

Finansiär

Finlands Akademi

Typ av finansiering

Forskardoktorer

Övriga uppgifter

Finansieringsbeslutets nummer

339167

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Biolääketieteet

Identifierade teman

cancer